AbbVie, Neurocrine drug successful in endometriosis trial
(Reuters) – An experimental drug being developed by AbbVie Inc and Neurocrine Biosciences Inc successfully reduced symptoms of endometriosis in pre-menopausal women in the first of two late-stage studies. Neurocrine's stock soared 24 percent to $27.20 in premarket trading on Thursday, while AbbVie's shares were up 1.7 percent at $68.10. Endometriosis occurs when the lining of the uterus grows outside of the womb, leading to chronic pelvic pain. It is the leading cause of infertility. …
